Merit Medical Systems (NASDAQ:MMSI) Stock Price Down 5.7% on Analyst Downgrade

Merit Medical Systems, Inc. (NASDAQ:MMSI)’s share price fell 5.7% on Friday after Needham & Company LLC lowered their price target on the stock from $101.00 to $90.00. Needham & Company LLC currently has a buy rating on the stock. Merit Medical Systems traded as low as $62.04 and last traded at $64.3140. 94,643 shares were traded during trading, a decline of 87% from the average session volume of 746,757 shares. The stock had previously closed at $68.18.

A number of other equities analysts have also recently commented on MMSI. Wall Street Zen cut shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 5th. Compass Point set a $107.00 price target on shares of Merit Medical Systems in a research note on Monday, April 20th. Barrington Research cut their price target on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a research note on Monday, April 20th. BTIG Research began coverage on shares of Merit Medical Systems in a research note on Friday, February 6th. They issued a “buy” rating and a $107.00 price target for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a research note on Friday, March 27th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.33.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q1 results beat expectations: revenue of ~$381.9M (up ~7% year‑over‑year) and non‑GAAP EPS $0.94, with margin improvement and stronger free cash flow. These operational beats underpin the company’s updated outlook. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $4.010–$4.150 (above street consensus ~3.93), signaling confidence in cash generation and profitability for the year. Merit Medical Q1 2026 Earnings Call Highlights
• Neutral Sentiment: Strategic portfolio moves: closed acquisition of View Point Medical for $140M ( ~$90M cash at close) to expand imaging/marker products; also sold the DualCap® assets for ~$28M (cash received). These reshape product mix but involve near‑term cash outflows/ins and integration work. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Neutral Sentiment: Company updated revenue presentation (Foundational vs Therapeutic) to better reflect end‑markets — useful for analysts/longer‑term modeling but unlikely to move the stock immediately. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Negative Sentiment: Analyst target trimmed: Needham lowered its price target from $101 to $90 while keeping a Buy rating, citing sector multiple compression and some growth deceleration — that haircut on the target likely pressured sentiment and contributed to selling. Analyst Reiterates Buy on Merit Medical Systems; Trims PT to $90
• Negative Sentiment: Market is focused on valuation and growth trajectory: despite beats, management noted growth is moderating vs prior periods — coupled with a ~31x P/E multiple, investors may be rotating out on multiple compression rather than fundamentals. Q1 2026 Earnings Call Transcript

Institutional Investors Weigh In On Merit Medical Systems

Several institutional investors have recently added to or reduced their stakes in MMSI. Lido Advisors LLC raised its stake in Merit Medical Systems by 3.8% during the 4th quarter. Lido Advisors LLC now owns 3,836 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 140 shares during the period. AMI Asset Management Corp increased its position in Merit Medical Systems by 0.8% in the first quarter. AMI Asset Management Corp now owns 21,818 shares of the medical instruments supplier’s stock worth $1,504,000 after purchasing an additional 168 shares during the last quarter. Sowell Financial Services LLC increased its position in Merit Medical Systems by 4.2% in the third quarter. Sowell Financial Services LLC now owns 4,355 shares of the medical instruments supplier’s stock worth $362,000 after purchasing an additional 174 shares during the last quarter. Maryland State Retirement & Pension System increased its position in Merit Medical Systems by 2.1% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,693 shares of the medical instruments supplier’s stock worth $766,000 after purchasing an additional 180 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Merit Medical Systems by 11.0% in the fourth quarter. Blue Trust Inc. now owns 1,853 shares of the medical instruments supplier’s stock worth $163,000 after purchasing an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Price Performance

The firm’s 50-day moving average is $70.68 and its two-hundred day moving average is $79.78. The company has a market cap of $3.84 billion, a P/E ratio of 30.50, a PEG ratio of 1.83 and a beta of 0.64. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.34 and a quick ratio of 2.95.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.96 by $0.08. The company had revenue of $393.94 million during the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a net margin of 8.48% and a return on equity of 13.82%. Merit Medical Systems’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.93 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Analysts anticipate that Merit Medical Systems, Inc. will post 3.61 earnings per share for the current year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.